RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

With RSV season approachgin, there are more options for those most susceptible to RSV, including a new vaccine and updated ...

The FDA approved RSV vaccine Abrysvo, which protects against lung infections, for high-risk adults as young as 18 with ...

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...

Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...